HERBALIFE® LIFTOFF® (AR CITRONA-LAIMA GARŠU) cits, šķīstošā tablete Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

herbalife® liftoff® (ar citrona-laima garšu) cits, šķīstošā tablete

vācijā pēc herbalife international luxembourg s.à r.l., c/o herbalife europe limited, the atrium, 1 harefield road, uxbridge, mi - cits, šķīstošā tablete

HERBALIFE® LIFTOFF® (AR APELSĪNU GARŠU) cits, šķīstošā tablete Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

herbalife® liftoff® (ar apelsĪnu garšu) cits, šķīstošā tablete

vācijā pēc herbalife international luxembourg s.à r.l., c/o herbalife europe limited, the atrium, 1 harefield road, uxbridge, mi - cits, šķīstošā tablete

Clopidogrel Acino Eiropas Savienība - latviešu - EMA (European Medicines Agency)

clopidogrel acino

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Eiropas Savienība - latviešu - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrela besilāts - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiskie līdzekļi - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmenta pacēlums, akūts miokarda infarkts, kopā ar asa, medicīniski ārstēti pacienti saņemt trombolītiskā terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. sīkāku informāciju, lūdzu, skatiet sadaļā 5.